Table 1.

Reasons for exclusion of 350 patients from the study.

94 previously published	[13,14]
33 with cardiac contraindication	11 non specified 10 prolonged QTc 3 Brugada syndrome 1 myocarditis history 1 left ventricular hypertrophy 1 severe ischemic cardiopathy 1 left bundle branch block 1 right bundle branch block 1 atrio-ventricular block 1 supraventricular tachycardia 1 ECG abnormalities suggesting underlying cardiac ischemic disease 1 unspecified arrhythmia
28 considered cured by the physician based on clinical feature
21 refusal of hydroxychloroquine or azithromycin treatment
15 with potential risk for drug interactions with hydroxychloroquine or azithromycin treatment	Cardiac drugs 3 flecainide 2 amiodarone 1 bisoprolol 1 nicardipine Neuropsychiatric drugs 2 escitalopram 1 levetiracetam 1 cyamemazine 1 venlafaxine 1 lamotrigine 1 valproate 1 lithium Others 1 cabergoline 1 dolutegravir/rilpivirine
10 hypokaliemia
6 children < 14 years
6 ophtalmologic contraindication to hydroxychloroquine treatment	3 retinopathy 2 glaucoma 1 accomodation disorder
4 known allergy to hydroxychloroquine or azithromycin treatment
2 breastfeeding
2 gastrointestinal intolerance to hydroxychloroquine or azithromycin treatment
2 swallowing disorders
1 insomnia
61 under hydroxychloroquine only before the publication of the first study [13] that led to the systematic use of dual therapy with azithromycin on March 20, 2020.
66 unspecified

The reasons mentioned here are those retained by physicians who have seen the patients and do not necessarily correspond to formal contraindications. Several reasons may coexist in the same patient.